Analysts Think Green Thumb Industries Will Double Over the Next 12 Months. Here's Why They're Probably Wrong - AOL

Green Thumb Industries, one of the few profitable cannabis stocks, is down more than 6% this year, but analysts’ average price target of $16 implies more than a doubling in the next 12 months. The article argues that a repeat-level move is unlikely without an extraordinary external macro or regulatory shock—most notably federal rescheduling of cannabis from Schedule I to Schedule III. It notes DOJ’s April order covering FDA-approved marijuana drugs and state-licensed medical cannabis is still facing legal challenges in the D.C. Circuit, with DEA hearings completed July 15 but final action deferred pending review. Even then, the post-280E benefit may be offset by new rules.